159 related articles for article (PubMed ID: 29089230)
41. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction.
Riedinger C; Endicott JA; Kemp SJ; Smyth LA; Watson A; Valeur E; Golding BT; Griffin RJ; Hardcastle IR; Noble ME; McDonnell JM
J Am Chem Soc; 2008 Nov; 130(47):16038-44. PubMed ID: 18959403
[TBL] [Abstract][Full Text] [Related]
42. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
44. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
45. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
Molecules; 2019 May; 24(10):. PubMed ID: 31121972
[TBL] [Abstract][Full Text] [Related]
46. Novel 1,2,4-triazole derivatives as apoptotic inducers targeting p53: Synthesis and antiproliferative activity.
Gomaa HAM; El-Sherief HAM; Hussein S; Gouda AM; Salem OIA; Alharbi KS; Hayallah AM; Youssif BGM
Bioorg Chem; 2020 Dec; 105():104369. PubMed ID: 33091670
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.
Yu Z; Zhuang C; Wu Y; Guo Z; Li J; Dong G; Yao J; Sheng C; Miao Z; Zhang W
Int J Mol Sci; 2014 Sep; 15(9):15741-53. PubMed ID: 25198897
[TBL] [Abstract][Full Text] [Related]
48. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
49. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
50. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
Leonard K; Marugan JJ; Raboisson P; Calvo R; Gushue JM; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3463-8. PubMed ID: 16647257
[TBL] [Abstract][Full Text] [Related]
51. Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Jeay S; Ferretti S; Holzer P; Fuchs J; Chapeau EA; Wartmann M; Sterker D; Romanet V; Murakami M; Kerr G; Durand EY; Gaulis S; Cortes-Cros M; Ruetz S; Stachyra TM; Kallen J; Furet P; Würthner J; Guerreiro N; Halilovic E; Jullion A; Kauffmann A; Kuriakose E; Wiesmann M; Jensen MR; Hofmann F; Sellers WR
Cancer Res; 2018 Nov; 78(21):6257-6267. PubMed ID: 30135191
[TBL] [Abstract][Full Text] [Related]
52. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
[TBL] [Abstract][Full Text] [Related]
53. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells.
Putri HE; Nutho B; Rungrotmongkol T; Sritularak B; Vinayanuwattikun C; Chanvorachote P
Phytomedicine; 2021 May; 85():153534. PubMed ID: 33773191
[TBL] [Abstract][Full Text] [Related]
54. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
55. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum
Liu W; Ma Y; He Y; Liu Y; Guo Z; He J; Han X; Hu Y; Li M; Jiang R; Wang S
J Med Chem; 2024 Jun; 67(11):9645-9661. PubMed ID: 38776419
[TBL] [Abstract][Full Text] [Related]
56. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
[TBL] [Abstract][Full Text] [Related]
57. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y
J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253
[TBL] [Abstract][Full Text] [Related]
58. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
[TBL] [Abstract][Full Text] [Related]
60. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
